Western blot shows recombinant mouse Serum Amyloid A1 and recombinant mouse Serum Amyloid A2. PVDF membrane was probed with 1 µg/mL of Goat Anti-Mouse Serum Amyloid A1/A2 Antigen Affinity-purified Polyclonal ...read more
Serum Amyloid A1/A2 was detected in perfusion fixed frozen sections of mouse liver using Goat Anti-Mouse Serum Amyloid A1/A2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2948) at 15 µg/mL overnight at 4 ...read more
Recombinant Mouse Serum Amyloid A1/A2 protein was serially diluted 2-fold and captured by Rat Anti-Mouse Serum Amyloid A1/A2 Monoclonal Antibody (Catalog # MAB2948) coated on a Clear Polystyrene Microplate ...read more
Western blot shows mouse serum and mouse plasma. PVDF membrane was probed with 1 µg/mL of Goat Anti-Mouse Serum Amyloid A1/A2 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2948) followed by ...read more
Simple Western lane view shows mouse serum, loaded at a 1:100 dilution. A specific band was detected for Serum Amyloid A1/A2 at approximately 14 kDa (as indicated) using 50 µg/mL of (Catalog # AF2948) followed ...read more
Detects mouse Serum Amyloid A1/SAA1 and mouse Serum Amyloid A2/SAA2 in direct ELISAs and Western blots. In direct ELISAs, less than 3% cross-reactivity with recombinant human (rh) SAA1, rhSAA2, recombinant mouse (rm) SAA3, and rmSAA4 is observed.
Test in a species/application not listed above to receive a full credit towards a future purchase.
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Serum Amyloid A1/A2 Antibody [Unconjugated]
Serum Amyloid A1/A2
Mouse serum amyloid A protein-1 (SAA1) is a multifunctional apolipoprotein produced by hepatocytes in response to pro-inflammatory cytokines. It is secreted as a 12 kDa, 103 amino acid (aa), nonglycosylated polypeptide and circulates as part of the HDL complex. The SAA1 gene is one of three SAA genes in mouse, and, based on human, is likely to be allelic. The SAA1 gene product differs from the SAA2 gene product by only nine amino acids. In human, circulating SAA1 shows multiple proteolytically-generated isoforms, with anywhere from one to three amino acids being cleaved from either the N- or C-terminus. The same situation may exist in mouse. The amino acid sequence of mature mouse SAA1 is 72%, 72%, 67%, and 74% identical to mature human, rabbit, equine, and hamster SAA1, respectively.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Serum Amyloid A1/A2 Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.